Explore the words cloud of the FiTTeR project. It provides you a very rough idea of what is the project "FiTTeR" about.
The following table provides information about the project.
Coordinator |
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Project website | http://www.stevensgroup.org/index.php/people/cat/researchers |
Total cost | 195˙454 € |
EC max contribution | 195˙454 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2016 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2017 |
Duration (year-month-day) | from 2017-08-21 to 2019-08-20 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE | UK (LONDON) | coordinator | 195˙454.00 |
As a Marie SkÅ‚odowska-Curie Fellow, I will develop, characterize, and determine the efficacy of a biomaterial platform to target pathologic fibrosis and promote tissue repair following myocardial infarction (MI). I have an ideal background and will perform well in this project based on my expertise in extracellular matrix (ECM) derived biomaterials, characterizing the immune response to biomaterials, and evaluating in vivo outcomes. The proposed system will consist of a protein fragment tethered to an injectable hydrogel. The hydrogel carrier will be composed of ECM, which has been shown to facilitate tissue repair processes by local modulation of immune cell phenotype . The cryptic protein fragment, recently isolated and recombinantly produced by the Stevens Group , has gained attention for its ability to regulate the onset of fibrosis by interfacing with cells to abrogate the release of matrix metalloproteinases (MMPs). No therapies currently exist to prevent or mitigate fibrosis. Developing a sophisticated delivery system for a cryptic protein fragment will enable the broad potential of targeting pathologic fibrosis to be realized. This system will be advantageous in simultaneously providing localized delivery, combined immunomodulatory and regulatory properties of the ECM and recombinant protein fragment, and sustained release of the protein fragment during degradation of the ECM hydrogel. The combination of my expertise (in ECM hydrogels, characterizing the host response to biomaterials, and translating technologies) and Prof Molly Stevens’s supervision and world-class interdisciplinary biomaterials-focused group, the 2014 Research Group of the Year (European Life Science Awards), at Imperial College London (ICL), together make this project ideally suited for success.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Gregor Fuhrmann, Rona Chandrawati, Paresh A. Parmar, Timothy J. Keane, Stephanie A. Maynard, Sergio Bertazzo, Molly M. Stevens Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy published pages: 1706616, ISSN: 0935-9648, DOI: 10.1002/adma.201706616 |
Advanced Materials 30/15 | 2020-03-06 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FITTER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FITTER" are provided by the European Opendata Portal: CORDIS opendata.